ClinicalTrials.gg
Active, not recruitingNCT07119489Updated Oct 23, 2026

A Novel Dialectical Behavior Therapy Brief Group Intervention for Cigarette Smoking by Patients With Cancer: An Open Clinical Trial

An interventional study of Dialectical Behavior Therapy -Skill Training brief intervention in Smoking Behavior, sponsored by Wake Forest University Health Sciences. Active, not recruiting at 2 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Wake Forest University Health Sciences · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 23, 2026Now Active, not recruitingStudy documents postedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
16
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Smoking by Wake Forest University Health Sciences — 2 open to participants now, 3 under way, none of them phase 3. Smoking · Wake Forest University Health Sciences.

Started
2026
the only one that year
No phase
8 of 10
2 open now
Registered
10th of 10
by date

Among the 10 studies in Smoking by Wake Forest University Health Sciences, this one is the only one that started in 2026, is one of 8 with no phase, and was the 10th registered.

Smoking

1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.

Browse Smoking studies →

Open to participants now

2 of the 10 studies in Smoking by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Smoking by Wake Forest University Health Sciences, or all of them as a file.
02

Study summary

The purpose of this research study is to learn more about how Dialectical Behavior Therapy - Skills Training can help patients with cancer who smoke cigarettes cut down on or stop their smoking.

Read the detailed description

This is a study that aims to evaluate recruitment rates, feasibility, acceptability, and fidelity of Dialectical Behavior Therapy - Skills Training (DBT-ST) brief intervention.

Study population will include participants who smoke and are undergoing treatment with curative intent for their cancer or are in remission.

The study will include eight 60 minute sessions of DBT-ST and measurements of psychological states and smoking habits by interventionists. At follow-up participants will complete a survey on their intervention experience and ongoing use of DBT-ST. Interventionists will also complete a survey following each session to record time and materials use for future cost-effectiveness analysis.

At follow-up, participants and interventionists will engage in a one-hour qualitative interview with a study team member.

03

Conditions studied

  • Smoking Behavior

Keywords

  • Dialectical Behavior Therapy
  • Cancer
  • Smoking
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Smoke ≥1 cigarettes every day in the past 30 days per participant report.
  2. Smoked at least 100 cigarettes (5 packs) in lifetime.
  3. Confirmation of cancer diagnosis at any time.
  4. Patient encounter with an AHWFBCCC provider within the last two years.
  5. Age ≥ 18 years at the time of consent.
  6. Ability to understand and willingness to sign an IRB-approved , in English, directly.
  7. Able and willing to participate in video conference.

Exclusion criteria

Exclusion Criteria:

  1. Patients actively receiving external tobacco use counseling or using tobacco cessation medications.
  2. Prior experience with more than five sessions of DBT-ST.
  3. Medical or psychiatric conditions limiting compliance with study requirements including suspected or reported cognitive impairment.
  4. Self-reported use of any psychoactive substance [except marijuana and nicotine] within the last 30 days.
  5. Have active and severe suicidal ideation at time of eligibility assessment or suicide attempt within the past month.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
16 participants (estimated)

Study arms

  • Experimental
    Patients with cancer who smoke

    Participants who smoke and are undergoing treatment with a curative intent for cancer or are in remission from cancer

    Behavioral: Dialectical Behavior Therapy -Skill Training brief intervention

Interventions

  • BehavioralDialectical Behavior Therapy -Skill Training brief intervention

    A behavioral counseling approach for enhancing skills in emotion regulation, distress tolerance, and mindfulness

06

What researchers measure

Primary outcomes

  1. Recruitment Rates

    Ratio of patients enrolled in study to patients responding to advertisement or referred by providers, and ratio of patients enrolled to patients screened and potentially eligible for the study.

    Time frame: Measured from the date the first patient responds to advertisement or is referred to the study by providers until the date the last patient group begins the first session of the intervention, assessed up to 100 weeks.

  2. Feasibility of the DBT-ST brief intervention for cigarette smoking by patients with cancer

    Rate of completion of the eight proposed sessions by participants

    Time frame: Measured from the date the first patient group begins the first session of the intervention until the date the last patient group completes the eighth session of the intervention, assessed up to 100 weeks.

  3. Acceptability of the DBT-ST brief intervention for cigarette smoking by patients with cancer

    Quantitative (Likert scale) questions to assess patient experience of intervention

    Time frame: For each patient group, measured at weeks 1 through 8 of the intervention and at 1 month follow-up, assessed up to 100 weeks.

  4. Fidelity of the DBT-ST brief intervention for cigarette smoking by patients with cancer

    Interventionist adherence to intervention manual will be assessed by having an independent reviewer select 50% of the audiotaped group sessions (the total depends on the number of groups) and complete a checklist of 25 intervention items (yes/no) to see whether the interventionist performed the item

    Time frame: Measured beginning 1 month after the date of week 8 of the final patient group participating in the intervention, assessed up to 6 months.

Secondary outcomes

  1. Cancer Patient Tobacco Use Questionnaire (C-TUQ)

    Changes in tobacco use, specifically number of days engaging in cigarette smoking (frequency) and number of cigarettes smoked per day (daily average) will be measured using the Cancer Patient Tobacco Use Questionnaire (C-TUQ) a 22-item self-report survey used to gather information about tobacco use by patients with cancer and cancer survivors.

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  2. Difficulties in Emotion Regulation Scale-36 (DERS-36)

    The Difficulties in Emotion Regulation Scale (DERS) is a 36-item self-report Likert scale used to assess emotional regulation presented as a total score and 6 sub-scores including nonacceptance of emotional responses, difficulty engaging in goal-directed behavior, impulse control difficulties, lack of emotional awareness, limited access to emotion regulation strategies, and lack of emotional clarity

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  3. Depression Anxiety Stress Scales-21 (DASS-21)

    The DASS-21 is a 21-item self-report instrument designed to measure the three related negative emotional states of depression, anxiety, and tension/stress.

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  4. Distress Tolerance Scale (DTS)

    Distress tolerance will be measured using the 15-item Distress Tolerance Scale (DTS). The DTS uses a 5-point Likert scale for participants to record responses to items (1 = 'Strongly Agree' to 5 = 'Strongly Disagree'). The total DTS score is calculated by adding the scores of all 15 items together after reverse-coding item 6 (score range 0-75)

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  5. Mindfulness Attention Awareness Scale (MAAS)

    Mindfulness will be measured using the Mindfulness Attention Awareness Scale (MAAS), a 15-item self-report instrument designed to assess a core characteristic of dispositional mindfulness, namely, open or receptive awareness of and attention to what is taking place in the present. The MAAS score is the mean of 15 Likert-scale items from 1-6 (score range 1-6)

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  6. Mental Adjustment to Cancer (MAC) Scale - Mini

    The MAC-Mini is a 29-item self-rating scale to assess psychological dimensions of in cancer patients of helplessness/hopelessness, anxious preoccupation, fatalism, avoidance, and fighting spirit in their adjustment to the diagnosis and treatment of cancer. Higher scores reflect lower levels of adjustment for all subscales except fighting spirit, with a higher score indicating higher adjustment

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  7. DBT Ways of Coping Checklist (DBT-WCCL)

    The DBT-WCCL is a 59-item self-report Likert scale, with one part assessing coping via DBT skills, the DBT Skills Subscale (DSS), and one part assessing coping via dysfunctional means, the Dysfunctional Coping Subscale (DCS).44 Skills use are measured on a scale from 0 (never used) to 3 (regularly used). Higher scores indicate more frequent use of DBT skills and functional coping behaviors.

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  8. Serious quit attempts

    The period of intentional abstinence from smoking typically lasting at least 24 hours, to be collected by self-report using a single item Serious Quit Attempt questionnaire

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

Other outcomes

  1. Self-reported cost for interventionist and patient time and expenses

    Self-reported cost for interventionist and patient time and expenses will be collected using an interventionist questionnaire

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  2. Costs of nicotine replacement therapy

    Costs of nicotine replacement therapy will be captured using a single item added to the Cancer Patient Tobacco Use Questionnaire (item 15a)

    Time frame: Measured at baseline, week 5, week 8, and at 1 month follow-up, assessed up to 100 weeks.

  3. Time between initial cancer diagnosis and administration of the DBT-ST intervention

    The impact on smoking cessation or reduction of the length of time between initial cancer diagnosis and administration of the DBT-ST intervention will be measured using the initial diagnosis date of any cancer per the patient's electronic health record and the Cancer Patient Tobacco Use Questionnaire

    Time frame: Measured from the date of initial cancer diagnosis until week 1 of the patient's participation in the intervention, assessed up to 100 weeks.

  4. Group Size

    The impact of group size on outcomes will be measured using the number of persons in each group, provided group size varies

    Time frame: Measured beginning 1 month after the date of week 8 of the final patient group participating in the intervention, assessed up to 6 months.

07

Study locations

2 sites
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Nov 2026, 9 months after the start.

Of 405 non-industry interventional studies with no phase under Smoking, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 42. This study's planned 9 months is below that.

Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 28, 2025
First posted
Aug 13, 2025
StartActual
Feb 11, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 23, 2026
Documents
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Active, not recruiting
    Documents Informed consent form ↗ posted
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07119489
Collaborators
Atrium Health Wake Forest Baptist, National Cancer Institute (NCI)
Responsible party
Sponsor
First posted
Aug 13, 2025
Start date
Feb 11, 2026
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 23, 2026

Study contacts

Marcia McCall, PhD
principal investigator · Wake Forest University Health Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion